53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
At CHEST 2025, held in Chicago, Illinois, Laurie Slovarp, PhD, CCC-SLP, professor at the University of Montana and certified speech pathologist, presented a poster on the development of a digital therapeutic designed to improve access to behavioral cough suppression therapy for patients with refractory chronic cough.
A large-scale trial examining the effect of azithromycin on the relationship between oesophageal function and cough as evaluated by Hyfe's cough monitoring technology in respiratory disease is feasible and acceptable to patients.
This study used Hyfe's wearable cough monitor during a 7-day run in, 28-day treatment, and 14-day follow-up period in patients with chronic bronchitis.
Periods of intense coughing (termed bouts, epochs or bursts) are particularly problematic for some coughers and may not be reflected by simply counting the number of coughs per day. This study explored how varying the definition of bouts yield different impressions of cough severity.
Cough is a ubiquitous health indicator whose global physical, psychological, and financial burden is extremeand underappreciated. As a disruptive, discrete, and information-rich symptom that is associated with a myriadof diseases, cough is also the ideal clinical endpoint. And yet, even in the age of mobile health, AI, and BigData, cough continues to be assessed mainly through subjective surveys and brief acoustic recordings withbulky and expensive clinical devices. Half the world population now carries smartphones that, when combinedwith AI-powered software, can be used as clinical tools for quantifying cough endpoints objectively.
Scalable mobile cough monitoring has the potential to transform clinical trials by increasing their success rate, decimatingtheir costs, accelerating products to market, and improving health equity worldwide.
